Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies
Executive Summary
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.
You may also be interested in...
Roche Partnering Finds Upfront Fee Relief In Current Market
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Value Of BioPharma M&A Leaps in Q3
Merck & Co's proposed acquisition of Acceleron and a couple of big purchases from Sanofi drove up the value of the sector's M&A activities, according to the latest report from Biomedtracker